Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.94 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30985618 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HSD17B10L3MBTL1SMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL15571781 | 0.97 | ALDH1A1 (0.90) | ALDH1A1HSD17B10L3MBTL1SMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL29427302 | 0.97 | ALDH1A1 (0.90) | ALDH1A1HSD17B10L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL25981 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HSD17B10L3MBTL1SMN1; SMN2HPGD | |
| Benzene SCHEMBL28328298 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HSD17B10L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL27950997 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HSD17B10L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL29407079 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HSD17B10L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL28465796 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HSD17B10L3MBTL1SMN1; SMN2HPGD | |
| Water SCHEMBL11160127 | 0.94 | ALDH1A1 (0.94) | ALDH1A1HSD17B10L3MBTL1SMN1; SMN2HPGD | |
| Biphenyl SCHEMBL10703079 | 0.94 | ALDH1A1 (0.94) | ALDH1A1HSD17B10L3MBTL1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146223-A | SNAP-tag probe and preparation and application thereof | 中国科学院大连化学物理研究所 | 2024-06-07 | — | — | CN | claimed |
| US-20250243170-A1 | REMIBRUTINIB DRUG SUBSTANCE AND DRUG PRODUCT SUBSTANTIALLY FREE OF NITROSAMINE IMPURITY | NOVARTIS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025137267-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2025-06-12 | — | — | US | disclosed |
| CN-119954801-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-114867727-B | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-119390681-A | Process for preparing COT inhibitor compounds | 吉利德科学公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4055019-B1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-116323589-A | Pyridone compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115677684-A | Substituted aryl or heteroaryl compounds | 先声药业有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20230024442-A1 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-115315423-A | Substituted aryl compounds | 先声药业有限公司 | 2022-11-08 | — | — | CN | disclosed |
| EP-4055019-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114874209-A | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114867727-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-110023302-B | 2,4, 5-trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114728941-A | Substituted 1, 5-naphthyridines or quinolines as ALK5 inhibitors | 施万生物制药研发IP有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-110461838-B | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | KRAS, NRAS, TP53 | ALDH1A1 3323/4885HSD17B10 3915/4885L3MBTL1 4356/4885 |
| US-20250243170-A1 | REMIBRUTINIB DRUG SUBSTANCE AND DRUG PRODUCT SUBSTANTIALLY FREE OF NITROSAMINE IMPURITY | ABL2, SRMS, TPMT | ALDH1A1 870/4885HSD17B10 3881/4885L3MBTL1 3954/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | ALDH1A1 2630/4885HSD17B10 3549/4885L3MBTL1 2712/4885 |
| US-20230024442-A1 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, XIAP, CBL | ALDH1A1 3861/4885HSD17B10 3607/4885L3MBTL1 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.